AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12502672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10190650 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (beta2-adrenoceptor partial agonist)
Number of subjects: 17
Study 10190650 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 17
Study 10190650 — intervention group
Group type: COMPARATOR
Intervention: ICI 118,551 (beta2-adrenoceptor antagonist)
Number of subjects: 17
Study 10190650 — intervention group
Group type: COMPARATOR
Intervention: ICI 118,551
Number of subjects: 17
Study 7672550 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable, sheathed, flexible sigmoidoscope
Number of subjects: 143
Study 7672550 — intervention group
Group type: COMPARATOR
Intervention: Standard sigmoidoscope
Number of subjects: 143
Study 1979207 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml solution)
Number of subjects: 12
Study 1979207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7013943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 400
Study 7013943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 400
Study 7013943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 31232970 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage and bone grafting combined with elastic intramedullary nailing (EIN)
Number of subjects: 62
Study 31232970 — intervention group
Group type: COMPARATOR
Intervention: Curettage and bone grafting alone (non-elastic intramedullary nailing - NEIN)
Number of subjects: 62
Study 28592029 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive proportional assist ventilation (PAV)
Number of subjects: 10
Study 28592029 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive pressure support ventilation (PSV)
Number of subjects: 10
Study 25734733 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam
Number of subjects: 1062
Study 25734733 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 1062
Study 25734733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study 23380515 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume (Hi-TV) of 10 mL/kg, rate of 7 breaths/min, zero positive end-expiratory pressure
Number of subjects: 34
Study 23380515 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume (Lo-TV) of 5 mL/kg, rate of 14 breaths/min, 5 cmH2O positive end-expiratory pressure
Number of subjects: 34
Study 21317598 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment integrated with HIV care
Number of subjects: 0
Study 21317598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing communication and technical assistance
Number of subjects: 0
Study 21317598 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive evaluation design
Number of subjects: 0
Study 19270469 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional disclosure intervention
Number of subjects: 68
Study 19270469 — intervention group
Group type: COMPARATOR
Intervention: Time management sessions
Number of subjects: 68
Study 17024925 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors
Number of subjects: 0
Study 17024925 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid antagonists
Number of subjects: 0
Study 17024925 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizers
Number of subjects: 0
Study 12885711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months exclusive breastfeeding
Number of subjects: 3483
Study 12885711 — intervention group
Group type: COMPARATOR
Intervention: 6 months exclusive breastfeeding
Number of subjects: 3483
Study 11605710 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthroposophic therapy
Number of subjects: 120
Study 11605710 — intervention group
Group type: COMPARATOR
Intervention: Conventional cancer treatment
Number of subjects: 120
Study 9526967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDP, Librium) 5 mg
Number of subjects: 23
Study 9526967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDP, Librium) 20 mg
Number of subjects: 23
Study 9526967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7510813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micrograms/kg per day by 30-min infusion for 28 days or until neutrophil recovery
Number of subjects: 315
Study 7510813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 2530384 — intervention group
Group type: EXPERIMENTAL
Intervention: h-alpha ANP infusion
Number of subjects: 7
Study 2530384 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Ve)
Number of subjects: 7
Study 1234013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (300 mug cumulative dose in three injections over 45 min)
Number of subjects: 10
Study 1234013 — intervention group
Group type: COMPARATOR
Intervention: Aerosol salbutamol
Number of subjects: 10
Study 1234013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol
Number of subjects: 10
Study 6795701 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU‐carmustine
Number of subjects: 109
Study 6795701 — intervention group
Group type: COMPARATOR
Intervention: ftorafur‐carmustine
Number of subjects: 109
Study 6795701 — intervention group
Group type: COMPARATOR
Intervention: Higher dosage of ftorafur (2 g/m2/day X 5 days)
Number of subjects: 109
Study 6795701 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU combination chemotherapy
Number of subjects: 109
Study 30857189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (SHHC)
Number of subjects: 0
Study 30857189 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29346597 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice a day for 12 weeks
Number of subjects: 24
Study 26590293 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599
Study 26590293 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study 24290606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/d) and kinako (29.14 g/d)
Number of subjects: 65
Study 24290606 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinako (29.14 g/d)
Number of subjects: 65
Study 24290606 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 65
Study 24290606 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (3 g/d)
Number of subjects: 65
Study 23662522 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 60
Study 23662522 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (sevoflurane)
Number of subjects: 60
Study 20680907 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional posterolateral thoracotomy (Group I, n=25)
Number of subjects: 50
Study 20680907 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing posterolateral thoracotomy (Group II, n=25)
Number of subjects: 50
Study 17625977 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% solution of 15 g fructose
Number of subjects: 20
Study 17625977 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% solution of 25 g fructose
Number of subjects: 20
Study 17625977 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% solution of 50 g fructose
Number of subjects: 20
Study 17625977 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% solution of 50 g fructose
Number of subjects: 20
Study 17625977 — intervention group
Group type: COMPARATOR
Intervention: Comparison of doses
Number of subjects: 20
Study 15989703 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) at 250 mg/m2 per day, starting 24 hours after completion of chemotherapy and continuing up to 48 hours before the next cycle.
Number of subjects: 34
Study 15989703 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide combination treatment.
Number of subjects: 34
Study 15989703 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) arm.
Number of subjects: 34
Study 11875707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 394
Study 11875707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin A overexpression
Number of subjects: 394
Study 11875707 — intervention group
Group type: EXPERIMENTAL
Intervention: Neu overexpression
Number of subjects: 394
Study 9833957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside therapy combined with a protease inhibitor (zidovudine + lamivudine + indinavir)
Number of subjects: 29
Study 9833957 — intervention group
Group type: COMPARATOR
Intervention: Nucleoside therapy alone
Number of subjects: 29
Study 9833957 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 29
Study 7621844 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 78
Study 7621844 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol
Number of subjects: 78
Study 7621844 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 78
Study 7621844 — intervention group
Group type: COMPARATOR
Intervention: arotinolol
Number of subjects: 78
Study 7621844 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 78
Study 2143062 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week structured psychiatric group intervention
Number of subjects: 35
Study 2143062 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 35
Study 353969 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (50 mg daily before bedtime)
Number of subjects: 40
Study 353969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 353969 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 40
Study 28951440 — intervention group
Group type: EXPERIMENTAL
Intervention: PYD-based sports mentorship program for 18 weeks, 90 minutes per session
Number of subjects: 664
Study 28951440 — intervention group
Group type: COMPARATOR
Intervention: Health education website (control)
Number of subjects: 664
Study 26447155 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1.8 g/d for 4 weeks
Number of subjects: 82
Study 24093344 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-Wait-Stop label
Number of subjects: 0
Study 24093344 — intervention group
Group type: COMPARATOR
Intervention: Standard label
Number of subjects: 0
Study 21812266 — intervention group
Group type: EXPERIMENTAL
Intervention: Qumin Tongbi Nasal Spraying Agent (QTNSA)
Number of subjects: 103
Study 21812266 — intervention group
Group type: COMPARATOR
Intervention: Veconase (Control)
Number of subjects: 103
Study 19708910 — intervention group
Group type: EXPERIMENTAL
Intervention: STORZ DCI video laryngoscope (VL)
Number of subjects: 56
Study 19708910 — intervention group
Group type: COMPARATOR
Intervention: Standard direct laryngoscopy (DL)
Number of subjects: 56
Study 17976096 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic pacing
Number of subjects: 36
Study 17976096 — intervention group
Group type: COMPARATOR
Intervention: Non-paced children
Number of subjects: 36
Study 17976096 — intervention group
Group type: EXPERIMENTAL
Intervention: All children
Number of subjects: 36
Study 17976096 — intervention group
Group type: EXPERIMENTAL
Intervention: All children with CCAVB
Number of subjects: 36
Study 17976096 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with DCM
Number of subjects: 36
Study 15114905 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyword method with keywords and images generated by the experimenter
Number of subjects: 363
Study 15114905 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyword method with keywords and images generated by themselves
Number of subjects: 363
Study 15114905 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyword method with keywords and images previously generated by peers
Number of subjects: 363
Study 15114905 — intervention group
Group type: COMPARATOR
Intervention: Rote method
Number of subjects: 363
Study 15114905 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-generated-keyword group
Number of subjects: 363
Study 15114905 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject generated keyword group
Number of subjects: 363
Study 15114905 — intervention group
Group type: COMPARATOR
Intervention: Rote method (Experiment 2)
Number of subjects: 363
Study 11413947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention (6-week duration)
Number of subjects: 92
Study 11413947 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 92
Study 9250258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (20,000 units)
Number of subjects: 24
Study 9250258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin (25 U/kg)
Number of subjects: 24
Study 9250258 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 8422173 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (surgical adjuvant chemotherapy with 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months for 6 times, and 800 mg/day of Futraful for one year)
Number of subjects: 2477
Study 8422173 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (surgical adjuvant chemotherapy)
Number of subjects: 2477
Study 8422173 — intervention group
Group type: COMPARATOR
Intervention: Group B (no treatment)
Number of subjects: 2477
Study 3538870 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 2000
Study 3538870 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 2000
Study 31490251 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS II block with local anesthetic and surgical infiltration with 0.9% saline (PECS group)
Number of subjects: 104
Study 31490251 — intervention group
Group type: COMPARATOR
Intervention: Surgical infiltration with local anesthetic and PECS II block with 0.9% saline (infiltration group)
Number of subjects: 104
Study 31490251 — intervention group
Group type: EXPERIMENTAL
Intervention: PECS II block
Number of subjects: 104
Study 31490251 — intervention group
Group type: COMPARATOR
Intervention: Surgical infiltration with local anesthetic
Number of subjects: 104
Study 31255174 — intervention group
Group type: EXPERIMENTAL
Intervention: StudyBuddy
Number of subjects: 44
Study 31255174 — intervention group
Group type: COMPARATOR
Intervention: IVR
Number of subjects: 44
Study 27673437 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (Endoscopic sinus surgery)
Number of subjects: 187
Study 27673437 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 187
Study 27673437 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-CRS subjects)
Number of subjects: 187
Study 25601535 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab 0.3 mg
Number of subjects: 759
Study 25601535 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 759
Study 25601535 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 759
Study 25601535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (both dosages)
Number of subjects: 759
Study 23967634 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + medication (Shugan Jianwei Anshen Decoction + acupuncture daily at specific points)
Number of subjects: 227
Study 23967634 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Deanxit, 1 tablet after getting up and after lunch)
Number of subjects: 227
Study 23967634 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine (Shugan Jianwei Anshen Decoction, 1 dose a day)
Number of subjects: 227
Study 21698503 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant transcatheter arterial chemoembolization (TACE)
Number of subjects: 125
Study 21698503 — intervention group
Group type: COMPARATOR
Intervention: Non-TACE (control group)
Number of subjects: 125
Study 18641208 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea consumption (4 cups or 960 mL per day)
Number of subjects: 0
Study 18641208 — intervention group
Group type: COMPARATOR
Intervention: Black tea consumption
Number of subjects: 0
Study 18641208 — intervention group
Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 0
Study 16528207 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3T-DWI
Number of subjects: 40
Study 16528207 — intervention group
Group type: COMPARATOR
Intervention: 1.5T-DWI
Number of subjects: 40
Study 14519794 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement capsule
Number of subjects: 60
Study 14519794 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement tablet
Number of subjects: 60
Study 14519794 — intervention group
Group type: EXPERIMENTAL
Intervention: High carotenoid diet
Number of subjects: 60
Study 14519794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10896881 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK octapeptide (CCK-8, 0.75 microgram infused over 10 min)
Number of subjects: 16
Study 10896881 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 10896881 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-A antagonist)
Number of subjects: 16
Study 8849632 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal self-disclosure
Number of subjects: 43
Study 8849632 — intervention group
Group type: COMPARATOR
Intervention: Nondisclosure discussion
Number of subjects: 43
Study 1613678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (4 x 60 mg)
Number of subjects: 32
Study 1613678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1613678 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 32
Study 6673899 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta loop IUD
Number of subjects: 260
Study 6673899 — intervention group
Group type: COMPARATOR
Intervention: Lippes loop D IUD
Number of subjects: 260
Study 31238972 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupressure (self-administered on five specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Number of subjects: 0
Study 31238972 — intervention group
Group type: COMPARATOR
Intervention: Non-specific acupressure (self-administered on five non-specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Number of subjects: 0
Study 28086146 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Psychoeducation (PEd)
Number of subjects: 304
Study 26218933 — intervention group
Group type: EXPERIMENTAL
Intervention: mild (minimally invasive lumbar decompression)
Number of subjects: 300
Study 26218933 — intervention group
Group type: COMPARATOR
Intervention: ESI (epidural steroid injections)
Number of subjects: 300
Study 26218933 — intervention group
Group type: EXPERIMENTAL
Intervention: mild
Number of subjects: 300
Study 26218933 — intervention group
Group type: COMPARATOR
Intervention: ESI
Number of subjects: 300
Study 23834353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low molecular weight heparin (LMWH) and prednisolone
Number of subjects: 52
Study 23834353 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) alone
Number of subjects: 52
Study 23834353 — intervention group
Group type: COMPARATOR
Intervention: No drugs
Number of subjects: 52
Study 21774287 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based chlorhexidine
Number of subjects: 100
Study 21774287 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 100
Study 19186898 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality performance strategies
Number of subjects: 32
Study 19186898 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality team charters and performance strategies
Number of subjects: 32
Study 19186898 — intervention group
Group type: COMPARATOR
Intervention: Poor quality performance strategies
Number of subjects: 32
Study 16888270 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA), 100 mg, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Number of subjects: 161
Study 16888270 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Number of subjects: 161
Study 15220785 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia-thoracic epidural analgesia (TEA)
Number of subjects: 1846
Study 15220785 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia-intrathecal analgesia (IT)
Number of subjects: 1846
Study 11506109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricated cuffs
Number of subjects: 45
Study 11506109 — intervention group
Group type: COMPARATOR
Intervention: Nonlubricated cuffs
Number of subjects: 45
Study 11506109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricated cuffs in critically ill patients
Number of subjects: 45
Study 8501369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infiltration
Number of subjects: 2
Study 8501369 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 2
Study 3123606 — intervention group
Group type: EXPERIMENTAL
Intervention: R-(-)-deprenyl
Number of subjects: 0
Study 3123606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31498877 — intervention group
Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 0
Study 31498877 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based phototherapy
Number of subjects: 0
Study 29921891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cyclophosphamide-based regimens (cyclophosphamide, cyclophosphamide + anthracycline, cyclophosphamide + ifosfamide + anthracycline)
Number of subjects: 553
Study 29921891 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed complete resection for clinical group‐III patients
Number of subjects: 553
Study 29921891 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parameningeal clinical group‐I patients
Number of subjects: 553